Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

(2020) T. Karn et al.   ANNALS OF ONCOLOGY

Prognostic Alternative mRNA Splicing Signature and a Novel Biomarker in Triple-Negative Breast Cancer

(2020) Qiang Liu et al.   DNA AND CELL BIOLOGY

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

(2020) Yi-Zhou Jiang et al.   CELL RESEARCH

Molecular Subtyping of Triple‐Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance

(2020) Shen Zhao et al.   ONCOLOGIST

Landscape of circulating tumour DNA in metastatic breast cancer

(2020) Andrew A. Davis et al.   EBioMedicine

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer

(2020) Jiande Wu et al.   Cancers

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

(2020) Antonio Marra et al.   npj Breast Cancer

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

(2020) Yue Gong et al.   Cell Metabolism

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

(2020) Javier Cortes et al.   LANCET

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

(2019) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies

(2019) Yi-Zhou Jiang et al.   CANCER CELL

Molecular Classification of Breast Cancer

(2019) Julia Y.S. Tsang et al.   ADVANCES IN ANATOMIC PATHOLOGY

Recent advances in triple negative breast cancer: the immunotherapy era

(2019) Antonio Marra et al.   BMC Medicine

Deep learning: new computational modelling techniques for genomics

(2019) Gökcen Eraslan et al.   NATURE REVIEWS GENETICS

Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes

(2019) Maggie L. DiNome et al.   ANNALS OF SURGICAL ONCOLOGY

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

(2019) H J Burstein et al.   ANNALS OF ONCOLOGY

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Expression of tumor-associated antigens in breast cancer subtypes

(2019) Giuseppe Curigliano et al.   BREAST

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

(2019) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

(2018) Carsten Denkert et al.   LANCET ONCOLOGY

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

(2018) Andrew Tutt et al.   NATURE MEDICINE

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer

(2018) Alec M. Chiu et al.   Scientific Reports

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

(2018) Leisha A. Emens et al.   JAMA Oncology

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Classification of triple-negative breast cancers based on Immunogenomic profiling

(2018) Yin He et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics

(2018) Jelmar Quist et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic profiling for the molecular classification of metastatic brain tumors

(2018) Javier I. J. Orozco et al.   Nature Communications

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

(2018) Jake R. Conway et al.   Genome Medicine

Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study

(2018) Weikai Xiao et al.   Cancer Management and Research

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Sung-Bae Kim et al.   LANCET ONCOLOGY

Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer

(2017) Thomas A Adams et al.   MODERN PATHOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes

(2017) Hiroko Masuda et al.   Oncotarget

Somatic gene mutation analysis of triple negative breast cancers

(2016) J.L. Dillon et al.   BREAST

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

(2016) Sebastian Moran et al.   LANCET ONCOLOGY

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

(2016) Carsten Denkert et al.   MODERN PATHOLOGY

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting

(2016) Luisa Carbognin et al.   ONCOLOGIST

The "cancer immunogram"

(2016) C. U. Blank et al.   SCIENCE

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Clinical implications of the intrinsic molecular subtypes of breast cancer

(2015) Aleix Prat et al.   BREAST

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

(2015) M. C. U. Cheang et al.   ONCOLOGIST

Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

(2015) Clare Stirzaker et al.   Nature Communications

The Proteomic Landscape of Triple-Negative Breast Cancer

(2015) Robert T. Lawrence et al.   Cell Reports

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour

(2013) Zeinab Elsawaf et al.   BREAST

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

(2012) L. Malorni et al.   BREAST CANCER RESEARCH AND TREATMENT

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY